15-Deoxy-Δ12,14-prostaglandin J2Induces Apoptosis and Upregulates SOCS3 in Human Thyroid Cancer Cells

Author:

Trindade-da-Silva Carlos Antônio123,Reis Carolina Fernandes14,Vecchi Lara1,Napimoga Marcelo Henrique5,Sperandio Marcelo5,Matias Colombo Bruna França1,Alves Patrícia Terra1,Ward Laura Sterian4,Ueira-Vieira Carlos2,Goulart Luiz Ricardo16

Affiliation:

1. Laboratory of Nanobiotechnology, Federal University of Uberlândia, 38400902 Uberlândia, MG, Brazil

2. Laboratory of Genetics, Federal University of Uberlândia, 38400902 Uberlândia, MG, Brazil

3. Hammock Laboratory of Pesticide Biotechnology, University of California Davis, Davis, CA 95616, USA

4. Laboratory of Cancer Molecular Genetics, University of Campinas, 13081-970 Campinas, SP, Brazil

5. Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and Research Center, 13045-755 Campinas, SP, Brazil

6. Department of Medical Microbiology and Immunology, University of California Davis, Davis, CA 95616, USA

Abstract

The cyclopentenone prostaglandin 15-deoxy-Δ12,14-prostaglandin J2(15d-PGJ2) is a natural ligand of peroxisome proliferator-activated receptor gamma (PPAR-γ) and a potential mediator of apoptosis in cancer cells. In the present study, we evaluated the effect of 15d-PGJ2in human thyroid papillary carcinoma cells (TPC-1) using different doses of 15d-PGJ2(0.6 to 20 μM) to determine IC50(9.3 μM) via the MTT assay. The supernatant culture medium of the TPC-1 cells that was treated either with 15d-PGJ2or with vehicle (control) for 24 hours was assessed for IL-6 secretion via CBA assay. RT-qPCR was used to evaluate mRNA expression of IL-6, SOCS1, SOCS3, and STAT3. TPC-1 cells treated with 15d-PGJ2decreased the secretion and expression of IL-6 and STAT3, while it increased SOCS1 and SOCS3. Overall, we demonstrated that 15d-PGJ2downregulated IL-6 signaling pathway and led TPC-1 cells into apoptosis. In conclusion, 15d-PGJ2shows the potential to become a new therapeutic approach for thyroid tumors.

Publisher

Hindawi Limited

Subject

Pharmacology (medical),Drug Discovery

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3